Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 651

1.

Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.

Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR.

Prostate Cancer Prostatic Dis. 2019 Aug 27. doi: 10.1038/s41391-019-0167-9. [Epub ahead of print]

PMID:
31455846
2.

Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.

Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium.

Eur Urol. 2019 Nov;76(5):693-702. doi: 10.1016/j.eururo.2019.07.041. Epub 2019 Aug 24.

PMID:
31451332
3.

Active surveillance for intermediate-risk prostate cancer: yes, but for whom?

Overland MR, Washington SL 3rd, Carroll PR, Cooperberg MR, Herlemann A.

Curr Opin Urol. 2019 Nov;29(6):605-611. doi: 10.1097/MOU.0000000000000671.

PMID:
31436567
4.

Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer.

Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M 3rd, Hope TA, Carroll PR, Feng FY.

Eur Urol Oncol. 2019 Jan 14. pii: S2588-9311(18)30194-9. doi: 10.1016/j.euo.2018.11.002. [Epub ahead of print]

PMID:
31411984
5.

Guidelines should be assessed based on the underlying evidence.

Carroll PR, Parsons JK.

CMAJ. 2019 Aug 6;191(31):E871. doi: 10.1503/cmaj.72508. No abstract available.

PMID:
31387962
6.

Reply by Authors.

Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC.

J Urol. 2019 Jul 31:10109701JU00005793126115939. doi: 10.1097/01.JU.0000579312.61159.39. [Epub ahead of print] No abstract available.

PMID:
31364932
7.

Hematuria Practice Guidelines That Explicitly Consider Harms and Costs.

Bauer SR, Carroll PR, Grady D.

JAMA Intern Med. 2019 Jul 29. doi: 10.1001/jamainternmed.2019.2269. [Epub ahead of print] No abstract available.

PMID:
31355847
8.

Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.

Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR.

Eur Urol. 2019 Jul 22. pii: S0302-2838(19)30536-6. doi: 10.1016/j.eururo.2019.07.012. [Epub ahead of print]

PMID:
31345635
9.

Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research.

Odisho AY, Bridge M, Webb M, Ameli N, Eapen RS, Stauf F, Cowan JE, Washington SL 3rd, Herlemann A, Carroll PR, Cooperberg MR.

JCO Clin Cancer Inform. 2019 Jul;3:1-8. doi: 10.1200/CCI.18.00084.

10.

A Mobile Health Intervention for Prostate Biopsy Patients Reduces Appointment Cancellations: Cohort Study.

Balakrishnan AS, Nguyen HG, Shinohara K, Au Yeung R, Carroll PR, Odisho AY.

J Med Internet Res. 2019 Jun 2;21(6):e14094. doi: 10.2196/14094.

11.

Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.

Masic S, Cowan JE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR.

Eur Urol Oncol. 2018 Oct;1(5):386-394. doi: 10.1016/j.euo.2018.04.018. Epub 2018 May 24.

PMID:
31158077
12.

Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor.

Balakrishnan AS, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR.

Urology. 2019 Sep;131:157-165. doi: 10.1016/j.urology.2019.05.018. Epub 2019 May 28.

PMID:
31150694
13.

SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.

Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC.

J Urol. 2019 May 30:101097JU0000000000000357. doi: 10.1097/JU.0000000000000357. [Epub ahead of print]

PMID:
31144591
14.

Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.

Westphalen AC, Fazel F, Nguyen H, Cabarrus M, Hanley-Knutson K, Shinohara K, Carroll PR.

Int Braz J Urol. 2019 Jul-Aug;45(4):713-723. doi: 10.1590/S1677-5538.IBJU.2018.0768.

15.

The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF.

Eur Urol. 2019 Sep;76(3):268-272. doi: 10.1016/j.eururo.2019.05.013. Epub 2019 May 23.

PMID:
31128968
16.

Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer.

Zuniga KB, Zhao S, Kenfield SA, Cedars B, Cowan JE, Van Blarigan EL, Broering JM, Carroll PR, Chan JM.

J Urol. 2019 May 15:101097JU0000000000000336. doi: 10.1097/JU.0000000000000336. [Epub ahead of print]

PMID:
31091175
17.

Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.

Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA.

AJR Am J Roentgenol. 2019 Aug;213(2):266-274. doi: 10.2214/AJR.18.20699. Epub 2019 Apr 30.

PMID:
31039025
18.

A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance.

Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR.

J Urol. 2019 Apr 26:101097JU0000000000000290. doi: 10.1097/JU.0000000000000290. [Epub ahead of print]

PMID:
31026214
19.

Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance of Early Stage Prostate Cancer.

Cedars BE, Washington SL 3rd, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR.

J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271. [Epub ahead of print]

PMID:
30958742
20.

Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.

Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR.

J Urol. 2019 Sep;202(3):506-510. doi: 10.1097/JU.0000000000000247. Epub 2019 Aug 8.

PMID:
30958738
21.

Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.

Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY.

Urology. 2019 Jul;129:165-171. doi: 10.1016/j.urology.2018.12.055. Epub 2019 Mar 27.

PMID:
30928607
22.

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.

JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096.

23.

Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer.

Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP.

J Urol. 2019 Jul;202(1):90-95. doi: 10.1097/JU.0000000000000175. Epub 2019 Jun 7.

PMID:
30810466
24.

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445. doi: 10.1038/s41391-018-0124-z. Epub 2019 Jan 21.

25.

Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer.

Kenfield SA, Van Blarigan EL, Ameli N, Lavaki E, Cedars B, Paciorek AT, Monroy C, Tantum LK, Newton RU, Signorell C, Suh JH, Zhang L, Cooperberg MR, Carroll PR, Chan JM.

Eur Urol. 2019 Jun;75(6):950-958. doi: 10.1016/j.eururo.2018.12.040. Epub 2019 Jan 10.

PMID:
30638635
26.

Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.

Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M 3rd, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA.

Urology. 2019 Mar;125:154-162. doi: 10.1016/j.urology.2018.09.038. Epub 2018 Dec 21.

PMID:
30580002
27.

Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.

Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR.

J Nucl Med. 2019 Jun;60(6):786-793. doi: 10.2967/jnumed.118.219501. Epub 2018 Dec 7.

PMID:
30530831
28.

Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.

Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y.

J Nucl Med. 2019 Jul;60(7):910-916. doi: 10.2967/jnumed.118.220715. Epub 2018 Nov 21.

PMID:
30464040
29.

Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial.

Winters-Stone KM, Kenfield SA, Van Blarigan EL, Moe EL, Ramsdill JW, Daniel K, Macaire G, Paich K, Kessler ER, Kucuk O, Gillespie TW, Lyons KS, Beer TM, Broering JM, Carroll PR, Chan JM.

JMIR Res Protoc. 2018 Nov 15;7(11):e11257. doi: 10.2196/11257.

30.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.

PMID:
30321406
31.

Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.

Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA.

Radiology. 2018 Dec;289(3):730-737. doi: 10.1148/radiol.2018180788. Epub 2018 Sep 18.

PMID:
30226456
32.

Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.

Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR.

Eur Urol. 2018 Nov;74(5):668-675. doi: 10.1016/j.eururo.2018.08.020. Epub 2018 Sep 1.

PMID:
30181067
33.

Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.

Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR.

J Urol. 2019 Feb;201(2):300-307. doi: 10.1016/j.juro.2018.08.047.

PMID:
30179620
34.

Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.

Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):117-124. doi: 10.1038/s41391-018-0084-3. Epub 2018 Aug 31.

PMID:
30171230
35.

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW.

J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065.

PMID:
30076904
36.

Effect of Oscillation on Perineal Pressure in Cyclists: Implications for Micro-Trauma.

Sanford T, Gadzinski AJ, Gaither T, Osterberg EC, Murphy GP, Carroll PR, Breyer BN.

Sex Med. 2018 Sep;6(3):239-247. doi: 10.1016/j.esxm.2018.05.002. Epub 2018 Jun 20.

37.

The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.

Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR.

Eur Urol. 2018 Oct;74(4):444-452. doi: 10.1016/j.eururo.2018.05.014. Epub 2018 May 28.

38.

USPTF Prostate Cancer Screening Recommendations-A Step in the Right Direction.

Carroll PR.

JAMA Surg. 2018 Aug 1;153(8):701-702. doi: 10.1001/jamasurg.2018.1283. No abstract available.

PMID:
29801146
39.

Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?

Spratt DE, Carroll PR.

J Clin Oncol. 2018 Oct 10;36(29):2914-2917. doi: 10.1200/JCO.2018.78.6236. Epub 2018 May 21. No abstract available.

PMID:
29782208
40.

Development of a stress response therapy targeting aggressive prostate cancer.

Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D.

Sci Transl Med. 2018 May 2;10(439). pii: eaar2036. doi: 10.1126/scitranslmed.aar2036.

41.

Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.

Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD.

Oncotarget. 2018 Jan 5;9(5):6550-6561. doi: 10.18632/oncotarget.23973. eCollection 2018 Jan 19.

42.

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y.

Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9.

43.

Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.

Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW.

Eur Urol. 2018 May;73(5):706-712. doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9.

44.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

45.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

46.

Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™).

Tat D, Kenfield SA, Cowan JE, Broering JM, Carroll PR, Van Blarigan EL, Chan JM.

Prostate. 2018 Jan;78(1):32-39. doi: 10.1002/pros.23441. Epub 2017 Nov 6.

47.

Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer.

Leapman MS, Wang ZJ, Behr SC, Kurhanewicz J, Zagoria RJ, Carroll PR, Westphalen AC.

Radiol Bras. 2017 Sep-Oct;50(5):299-307. doi: 10.1590/0100-3984.2016.0117.

48.

Cycling, and Male Sexual and Urinary Function: Results from a Large, Multinational, Cross-Sectional Study.

Awad MA, Gaither TW, Murphy GP, Chumnarnsongkhroh T, Metzler I, Sanford T, Sutcliffe S, Eisenberg ML, Carroll PR, Osterberg EC, Breyer BN.

J Urol. 2018 Mar;199(3):798-804. doi: 10.1016/j.juro.2017.10.017. Epub 2017 Oct 13.

PMID:
29031767
49.

Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).

Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR.

PLoS One. 2017 Oct 10;12(10):e0185535. doi: 10.1371/journal.pone.0185535. eCollection 2017.

50.

Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.

Zhou CK, Stanczyk FZ, Hafi M, Veneroso CC, Lynch B, Falk RT, Niwa S, Emanuel E, Gao YT, Hemstreet GP, Zolfghari L, Carroll PR, Manyak MJ, Sesterhenn IA, Levine PH, Hsing AW, Cook MB.

Prostate. 2017 Dec;77(16):1573-1582. doi: 10.1002/pros.23433. Epub 2017 Oct 2.

Supplemental Content

Loading ...
Support Center